- Novartis’ Leqvio® (inclisiran) showed significant LDL-C reduction as monotherapy in low/moderate ASCVD risk patients in the Phase III V-MONO study, meeting primary endpoints versus placebo and ezetimibe.
- Results from study involving 60,000 patients.
- Leqvio, a biannual siRNA therapy, helps manage cholesterol adherence issues and is approved in nearly 100 countries.
August 28 2024 05:15:49 UTC– Novartis has announced promising results from a study on Leqvio, a treatment aimed at lowering “bad” cholesterol (LDL-C) in people at low to moderate risk of heart disease.
The study, part of a larger research effort called the VictORION program, showed that Leqvio significantly reduced LDL-C levels.
Leqvio is a therapy that needs to be taken only twice a year and has already been approved in several countries.
Novartis plans to share these findings with health regulators and continue exploring Leqvio’s potential in preventing heart disease.
Novartis announced positive results from the Phase III V-MONO study on Leqvio, showing significant LDL-C reduction in low to moderate ASCVD risk patients.
Leqvio is a twice-yearly siRNA therapy approved in multiple countries.
Novartis aims to present data to regulatory agencies and continue research on Leqvio for primary and secondary prevention of ASCVD.